Skip to main
EXEL

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 38%
Buy 19%
Hold 44%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis Inc has demonstrated strong momentum in its core product, Cabometyx, particularly in the first-line renal cell carcinoma (RCC) and second-line neuroendocrine tumors (NET) markets, where it commands a 46% market share with a 15% year-over-year growth in total prescription volume. The company has strategically expanded its gastrointestinal sales team to capitalize on the growing demand for Cabometyx and prepare for the launch of zanzalintinib in colorectal cancer, bolstered by favorable results from the Phase 3 STELLAR-303 trial, which showed a statistically significant improvement in overall survival. Additionally, Exelixis's robust balance sheet and projections for increased Cabometyx sales—estimated to reach $2.8 billion by FY28—further underscore its potential for sustainable profitability and market leadership in oncology therapeutics.

Bears say

Exelixis Inc has reported a decline in its gross-to-net (GTN) from 30.2% in 3Q25 to 28.5% in 4Q25, primarily due to decreased PHS/340B volumes, raising concerns about revenue sustainability. Cabometyx sales reached $545 million in 4Q25, which was below both the company's and consensus estimates, contributing to an uncertain outlook for future growth in the increasingly competitive markets of renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Additionally, several risks jeopardize Exelixis's financial health, including potential commercial limitations for Cabometyx, the possibility of unfavorable data from ongoing clinical trials, generic erosion of its established franchises, and long-term dilution risks.

Exelixis (EXEL) has been analyzed by 16 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 19% recommend Buy, 44% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 16 analysts, Exelixis (EXEL) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.